Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Pulmonary hypertension (PHT) patients often receive long term oral anticoagulants. If the
indication is strong, in the secondary chronic thrombo-embolism pulmonary hypertension
(CTE-PHT) prevention, the frequent prescription (50 to 90% of patients) contrasts with their
low level of proof in the PHT. Last but not least, anticoagulants are known to be the
principal cause of iatrogenic hospitalization (major bleeding).
In this study, patients are all followed during one year, to determine the annual frequency
of major bleedings (according to the International Society on Thrombosis and Haemostasis
(ISTH) international definition). Each event notified is validated by an independent
committee for clinical events.